for the shorter RFS prediction, the contribution of MRD data to the multivariable model’s accuracy was more pronounced than for the RFS model built initially (C-statistics of 0.78 and 0.65 for 6- and 12-month RFS without MRD data). As a caveat, there were only 18 events in the 6-month RFS analysis, limiting the inference that can be drawn from the multivariable models; larger cohorts will be needed to test this idea further. If confirmed, our studies may form the basis for the development of relatively accurate shorter-term RFS prediction models in which MRD data should be included.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

Research reported in this publication was supported by grants from the National Cancer Institute/National Institutes of Health (NCI/NIH; CA182010 to RBW and MO, CA160872 to DLS, and CA090998 to MO). The S0106 study was conducted by SWOG and supported by NIH/NCI/NCCTN Grants CA180888, CA180819, CA180828 and CA180944; NCI Grant CA182010, and in part by Wyeth (Pfizer) Pharmaceuticals, Inc. RBW is a Leukemia & Lymphoma Society Scholar in Clinical Research.

REFERENCES

1 Walter RB, Othus M, Burnett AK, Løwenberg B, Kantarjian HM, Ossenkoppele GJ et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. *Leukemia* 2015; 29: 312–320.

2 Walter RB, Othus M, Paetel EM, Racevskis J, Fernandez HF, Lee JW et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. *Leukemia* 2015; 29: 2104–2107.

3 Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. *Blood* 2013; 121: 4854–4860.

4 Araki D, Wood BL, Othus M, Radich JP, Halpem AB, Zhou Y et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? *J Clin Oncol* 2016; 34: 329–336.

5 Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpem AB et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. *Leukemia* 2016; 30: 1456–1464.

6 Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. *J Clin Oncol* 2011; 29: 4417–4423.

7 Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42 A study. *J Clin Oncol* 2013; 31: 3889–3897.

8 Freeman SD, Virgo P, Couzens S, Grimmwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. *J Clin Oncol* 2013; 31: 4123–4131.

9 Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *J Clin Oncol* 2015; 33: 1258–1264.

10 Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. *Blood* 2007; 110: 4172–4174.

11 Lacombe F, Amoulet C, Maynadie M, Lippert E, Luquet I, Pignieux A et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. *Leukemia* 2009; 23: 350–357.

12 Vainstein V, Buckley SA, Shukron G, Estey EH, Abkowitz JL, Wood BL et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in adult patients with acute myeloid leukemia. *J Clin Oncol* 2008; 26: 4944–4951.

13 Ofран Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R et al. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the ‘3+7’ induction regimen for acute myeloid leukemia. *Am J Hematol* 2015; 90: 1159–1164.

14 Maurillo L, Buccianese F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. *J Clin Oncol* 2008; 26: 713–716.

15 Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al. Assessment of minimal residual disease in standard-risk AML. *N Engl J Med* 2016; 374: 422–433.

OPEN

Germline heterozygous *DDX41* variants in a subset of familial myelodysplasia and acute myeloid leukemia

*Leukemia* (2016) 30, 2083–2086; doi:10.1038/leu.2016.124

Myelodysplasia (MDS) and acute myeloid leukemia (AML) are mostly sporadic hematopoietic stem cell clonal disorders. However, there are rare occurrences of familial MDS/AML where there are two or more affected cases in the same family. To date, germline heterozygous mutations have been identified in 10 genes (*RUNX1*, *CEBPA*, *TERC*, *TERT*, *GATA2*, *SRP72*, *ANKRD26*, *ACD*, *ETV6* and *DDX41*)11–10 associated with familial MDS/AML. Over the last 15 years we have accrued 78 families in which there are at least two cases of bone marrow failure and at least
one of whom has MDS or AML. We have undertaken a combination of whole-exome and targeted sequencing to characterize these families. The targeted sequencing uses a newly designed familial MDS/AML gene panel that includes the above 10 listed genes. This analysis has enabled us to identify four families harboring heterozygous germline \textit{DDX41} (DEAD-box helicase 41) variants (Figures 1a–d); three families have novel frameshift variants (c.155dupA, c.1586_1587delCA and c.719delTinsCG) and the fourth family has a recurrent missense variant in the initiation codon (c.3G>A, rs141601766) described previously by Lewinsohn et al.\textsuperscript{11} Collectively, these four families comprise seven cases of MDS and two cases of AML (age range, 40–70 years). These patients did not have any extra-hematopoietic features and therefore represent ‘pure’ MDS/AML (Table 1).

At present, little is known about DDX41 function and its role in hematopoiesis. However, Polprasert et al.\textsuperscript{10} showed that the protein encoded by \textit{DDX41} interacts directly with spliceosomal proteins and inactivation of tumor suppressors can occur once this interaction is disrupted. It is known that members of the DEAD/H box RNA helicase family can act as oncogenes or tumor suppressors in other cancers, depending on the specific protein interactions.\textsuperscript{12} In addition, alterations in \textit{DDX41} can cause exon skipping or exon retention in the RNA-splicing process resulting in alteration of specific genetic isoforms.\textsuperscript{10}

\textbf{Figure 1.} (a–d) Families with MDS–AML with variants in \textit{DDX41}, their age at diagnosis and their respective Sanger sequencing traces. Affected individuals are colored as follows: red, MDS; yellow, CML; black, AML; and green, other non-hematological cancer. (e) Schematic of \textit{DDX41} protein showing the heterozygous variants identified in this study. CML, chronic myeloid leukemia.
Kirwan et al. demonstrated that familial MDS/AML patients with germline variants in TERT and TERC have significantly shorter telomeres compared with controls. To determine whether our group of ‘pure’ MDS/AML patients with germline DDX41 variants have a similar impact on telomere length, we measured peripheral blood telomere length by monochrome multiplex quantitative PCR method in our patients. Slightly shorter telomere length was found in this group of patients harboring germline DDX41 variants compared with age-matched controls (P < 0.05, Supplementary Figure S1). It will be important to investigate telomere length in additional patients with DDX41 variants to substantiate these observations.

In Family 1 (Figure 1a), a novel heterozygous germline variant c.155dupA (p.Arg53Alafs*16 showed in Figure 1e) in DDX41 was identified in the 49-year-old female index case (II-1) diagnosed with MDS, refractory anemia with excess blasts (RAEB). Sanger sequencing revealed that her maternal uncle and aunt who both developed RAEB also harbor this frameshift variant (individuals II-2 and II-3, respectively). There are two asymptomatic carriers (individuals II-1 and II-4), supporting previous observations that haploinsufficiency for DDX41 shows variable penetrance. Further family history included her father (I-2) who died of chronic myeloid leukemia, unlikely to be related to the DDX41 variant.

In Family 2 (Figure 1b), the index case is a 60-year-old male (II-1) with AML harboring a novel heterozygous frameshift variant c.719delTinsCG (p.Ile240Thrfs*108), predicted to cause truncation of the protein and consequent loss of function. His mother died of AML (I-1). Segregation analysis was not possible as there were no family samples available, however the variant allele frequency in the index case is 0.494 indicating a heterozygosity. This variant is located in the DEAD-box domain of DDX41, in a highly conserved motif that includes the ATP-binding site of DDX41 (Figure 1e), which is again predicted to cause truncation of the protein. Her brother has tongue cancer (II-4), his mother has MDS (I-1) and her father has stomach cancer (I-2). In the absence of samples of the index case’s parents, Sanger sequencing was undertaken on samples from her siblings and children. The asymptomatic carrier (II-2) is an asymptomatic carrier. This suggests that the index case and her mother (both with MDS) have disease associated with the DDX41 variant, while the non-hematological cancers seen in her brother (II-4) and father (I-2) are unrelated to DDX41.

The index case of Family 4 (Figure 1d) is a 41-year-old female (I-1) diagnosed with MDS/RAEB. Her father (I-2) was also diagnosed with MDS at the age of 64 years. The heterozygous missense variant c.3G>A (p.Met1Ile—rs141601766, showed in Figure 1e) in DDX41, which segregated with disease in these two individuals, has been reported in The Exome Aggregation Consortium (ExAC) database in 6/117 464 alleles (http://exac.broadinstitute.org/, accessed 31 March 2016). Interestingly, both cases with the c.3G>A variant also carried a linked 5′-untranslated region variant (c.-44G>A) (shown in Figure 1d) previously observed by Lewinsohn et al. They also demonstrated that human embryonic kidney 293 cells (HEK-293) cells ectopically expressing the Met1Ile mutant protein used an alternative translation initiation site yielding a smaller DDX41 protein when compared with the full-length of 70 kDa. Their experiments suggest that this isoform may occur naturally and has an altered location.

The recurrence of the Met1Ile variant in the ExAC database poses an interesting question as to the causative role of DDX41 variants in MDS/AML. Excluding any non-canonical and dubious calls in this database, loss of function (LOF) variants (including Met1Ile) are seen to occur at a cumulative frequency of 1 in 1189 people (46 LOF variants in an average of 109 354 alleles). This is in stark contrast to the few LOF variants reported in RUNX1 (6), CEBPA (0), GATA2 (0) and ETF6 (1). We also note that in a screen of 1034 patients

**Table 1. Characteristics and family history of index cases**

| Family | Case | Age (years) | Diagnosis | Relationship to index | Nucleotide | Amino acid |
|--------|------|-------------|-----------|-----------------------|------------|------------|
| I      | I-1  | NA          | Asymptomatic | Grandmother | NA         | NA         |
|        | I-2  | NA          | Asymptomatic | Grandfather | NA         | NA         |
| II     | II-1 | 77          | Asymptomatic | Maternal aunt | c.155dupA | p.Arg53Alafs*16 |
|        | II-2 | 69          | MDS         | Maternal uncle | c.155dupA | p.Arg53Alafs*16 |
|        | II-3 | 66          | MDS         | Maternal aunt | c.155dupA | p.Arg53Alafs*16 |
|        | II-4 | NA          | Asymptomatic | Mother      | NA         | NA         |
|        | II-5 | NA          | CML         | Father      | NA         | NA         |
| III    | III-1| 49          | MDS         | Index case  | c.155dupA | p.Arg53Alafs*16 |
|        | II    | NA          | AML         | Mother      | NA         | NA         |
|        | II-1 | NA          | Asymptomatic | Father      | NA         | NA         |
|        | II-2 | 60          | AML         | Index case  | c.719delTinsCG | p.Ile240Thrfs*108 |
|        | II-1 | NA          | MDS         | Mother      | NA         | NA         |
|        | II-2 | NA          | Stomach cancer | Father   | NA         | NA         |
|        | II-3 | 56          | Tongue cancer | Brother | NV         | NV         |
|        | II-1 | NA          | Asymptomatic | Son        | NV         | NV         |
|        | II-2 | NA          | Asymptomatic | Daughter   | c.1586-1587delCA | p.Asn626del*12 |
|        | II-1 | NA          | Asymptomatic | Mother     | NA         | NA         |
|        | I-1  | NA          | MDS         | Father      | c.3G>A     | p.Met1Ile  |
|        | I-2  | 64          | MDS         | Father      | c.3G>A     | p.Met1Ile  |
|        | II-1 | 41          | MDS         | Index case  | c.3G>A     | p.Met1Ile  |

Abbreviations: MDS, myelodysplastic syndrome; NA, not available; NV, does not have the variant.
with MDS and secondary AML, 7 patients (1 in 148) had germline LOF variants in DDX41 (ref. 10). These data indicate that rather than establishing a causal Mendelian link between germline LOF DDX41 variants and MDS/AML, it is better to think of them as genetic risk factors. Comparing the frequency of LOF DDX41 variants seen in MDS and secondary AML with the frequency seen in ExAC we obtain an odds ratio of 8.05 \( (P=5.65 \times 10^{-5}, \text{ Fisher’s exact test}) \). Allowing for a 1/100 probability of getting the disease, this would translate to a relative risk of 7.51. It is inevitable therefore, that MDS/AML driven by DDX41 LOF variants will sometimes appear as familial.

In summary, we report on novel germline heterozygous DDX41 variants exhibiting variable penetrance in families with MDS/AML and tendency to short telomeres. Our analysis suggests that rather than establishing a causal Mendelian link between DDX41 germline LOF variants and MDS/AML it is appropriate to consider these as genetic risk factors.

**CONFLICT OF INTEREST**
The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**
This work was supported by CNPq (The Brazilian National Council for Scientific and Technological Development), Bloodwise, Children with Cancer and MRC (Medical Research Council, UK).

SR Cardoso1,4, G Ryan2,4, AJ Walne1, A Ellison1, R Lowe1, H Tummala1, A Rio-Machín1,3, L Collopy1, A Al Seraihi2, Y Wallis2, P Page2, S Akiki2, J Fitzgibbon3, T Vulliamy1,5 and I Dokal1,5

1 Centre for Genomics and Child Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts NHS Trust, London, UK;
2 Birmingham Women’s NHS Foundation Trust, Birmingham, UK and
3 Centre for Haemato-Oncoology, Barts Cancer Institute, Queen Mary University of London, London, UK
4 These authors contributed equally to this work.
5 These authors are joint senior authors.

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

---

### Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation

*Leukemia* (2016) **30**, 2086–2089; doi:10.1038/leu.2016.125

Allogeneic hematopoietic stem cell transplantation (alloSCT) is a valuable treatment option with curative potential for patients with relapsed and refractory non-Hodgkin's lymphoma (NHL), but its use has been limited by matched donor availability. Haplo-identical stem cell transplantation (haplo-SCT) has been developed to address this limitation. Virtually all patients have a haplotype-mismatched family donor, who is immediately available. The recent development of haplo-SCT protocols, involving high-dose post-transplant cyclophosphamide (ptCY) given early after graft infusion has led to a continuously growing popularity of haplo-SCT. Although the data in myeloid diseases and Hodgkin's lymphoma is